 Paul Toren
Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aryl Hydrocarbon Hydroxylases | 3 | 2024 | 45 | 0.390 |
Why?
| | Proton Pump Inhibitors | 2 | 2024 | 18 | 0.330 |
Why?
| | Chromatography, High Pressure Liquid | 8 | 2022 | 40 | 0.270 |
Why?
| | Ketotifen | 1 | 2024 | 3 | 0.240 |
Why?
| | Cross-Over Studies | 1 | 2024 | 35 | 0.240 |
Why?
| | Eosinophilia | 1 | 2024 | 29 | 0.230 |
Why?
| | Dyspepsia | 1 | 2024 | 53 | 0.220 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2024 | 96 | 0.220 |
Why?
| | Microsomes, Liver | 5 | 2020 | 44 | 0.200 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 20 | 0.200 |
Why?
| | Trimethoprim | 1 | 2022 | 11 | 0.200 |
Why?
| | Pimozide | 1 | 2020 | 4 | 0.180 |
Why?
| | Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2020 | 11 | 0.180 |
Why?
| | Antipsychotic Agents | 1 | 2020 | 14 | 0.180 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2020 | 46 | 0.180 |
Why?
| | Enkephalin, Leucine | 1 | 2018 | 1 | 0.160 |
Why?
| | Peptidomimetics | 1 | 2018 | 1 | 0.160 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2020 | 184 | 0.160 |
Why?
| | Humans | 12 | 2024 | 6896 | 0.150 |
Why?
| | Neprilysin | 1 | 1995 | 1 | 0.130 |
Why?
| | Protease Inhibitors | 1 | 1995 | 2 | 0.130 |
Why?
| | Benzazepines | 1 | 1995 | 4 | 0.130 |
Why?
| | Pyridines | 1 | 1995 | 4 | 0.130 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 1995 | 3 | 0.130 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 1995 | 15 | 0.130 |
Why?
| | Enzyme Inhibitors | 2 | 2011 | 21 | 0.120 |
Why?
| | Child | 4 | 2024 | 3364 | 0.110 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 3 | 0.110 |
Why?
| | Amines | 1 | 2012 | 4 | 0.110 |
Why?
| | Metabolomics | 1 | 2012 | 18 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2022 | 199 | 0.100 |
Why?
| | Ticlopidine | 1 | 2011 | 2 | 0.100 |
Why?
| | Cytochrome P-450 Enzyme Inhibitors | 1 | 2011 | 6 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2011 | 11 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2011 | 37 | 0.090 |
Why?
| | Female | 4 | 2024 | 3525 | 0.090 |
Why?
| | Drug Interactions | 3 | 2020 | 32 | 0.090 |
Why?
| | Male | 5 | 2024 | 3337 | 0.080 |
Why?
| | Peptide Fragments | 2 | 1988 | 12 | 0.080 |
Why?
| | Biotransformation | 3 | 2020 | 49 | 0.080 |
Why?
| | Cytochrome P-450 CYP2C19 | 2 | 2024 | 60 | 0.080 |
Why?
| | Rifampin | 2 | 1998 | 7 | 0.080 |
Why?
| | Antitubercular Agents | 2 | 1998 | 7 | 0.080 |
Why?
| | Adolescent | 3 | 2024 | 2197 | 0.080 |
Why?
| | Insulin | 1 | 1988 | 50 | 0.080 |
Why?
| | Drug Stability | 2 | 2018 | 4 | 0.070 |
Why?
| | Recombinant Proteins | 2 | 2020 | 48 | 0.070 |
Why?
| | Animals | 3 | 2018 | 729 | 0.070 |
Why?
| | Gemfibrozil | 1 | 2005 | 1 | 0.070 |
Why?
| | Glucuronides | 1 | 2005 | 3 | 0.070 |
Why?
| | Molecular Structure | 2 | 2018 | 4 | 0.070 |
Why?
| | Microsomes | 2 | 2018 | 5 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2024 | 5 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2024 | 44 | 0.060 |
Why?
| | Intestinal Mucosa | 1 | 2024 | 41 | 0.060 |
Why?
| | Pilot Projects | 1 | 2024 | 120 | 0.060 |
Why?
| | Haplotypes | 1 | 2024 | 91 | 0.060 |
Why?
| | Abdominal Pain | 1 | 2024 | 71 | 0.050 |
Why?
| | Genotype | 1 | 2024 | 410 | 0.050 |
Why?
| | Plasma | 1 | 2022 | 7 | 0.050 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2022 | 13 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2024 | 622 | 0.050 |
Why?
| | Middle Aged | 2 | 2020 | 608 | 0.050 |
Why?
| | Tourette Syndrome | 1 | 2020 | 6 | 0.050 |
Why?
| | Mass Spectrometry | 3 | 2005 | 18 | 0.050 |
Why?
| | Aged | 1 | 2020 | 378 | 0.040 |
Why?
| | Adult | 2 | 2020 | 1181 | 0.040 |
Why?
| | Solubility | 1 | 2018 | 2 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2018 | 29 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 19 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 1 | 2018 | 50 | 0.040 |
Why?
| | Young Adult | 1 | 2020 | 647 | 0.040 |
Why?
| | Brain | 1 | 2018 | 80 | 0.040 |
Why?
| | Protein Binding | 2 | 2011 | 31 | 0.030 |
Why?
| | Freezing | 1 | 1995 | 1 | 0.030 |
Why?
| | Spectrophotometry, Ultraviolet | 1 | 1995 | 1 | 0.030 |
Why?
| | Sulfhydryl Compounds | 1 | 1995 | 1 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1995 | 6 | 0.030 |
Why?
| | Dogs | 1 | 1995 | 17 | 0.030 |
Why?
| | Diltiazem | 1 | 2012 | 1 | 0.030 |
Why?
| | Data Mining | 1 | 2012 | 5 | 0.030 |
Why?
| | Workflow | 1 | 2012 | 6 | 0.030 |
Why?
| | Esomeprazole | 1 | 2011 | 1 | 0.020 |
Why?
| | Lansoprazole | 1 | 2011 | 1 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 7 | 0.020 |
Why?
| | Hepatocytes | 1 | 2011 | 8 | 0.020 |
Why?
| | 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2011 | 6 | 0.020 |
Why?
| | Omeprazole | 1 | 2011 | 13 | 0.020 |
Why?
| | Anti-Ulcer Agents | 1 | 2011 | 8 | 0.020 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2011 | 25 | 0.020 |
Why?
| | Indicator Dilution Techniques | 1 | 2011 | 1 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2011 | 16 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2011 | 23 | 0.020 |
Why?
| | Amino Acids | 2 | 1988 | 5 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 1988 | 32 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2011 | 20 | 0.020 |
Why?
| | Carbon Radioisotopes | 2 | 1998 | 2 | 0.020 |
Why?
| | Feces | 2 | 1998 | 37 | 0.020 |
Why?
| | Models, Chemical | 1 | 1988 | 1 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 2 | 0.020 |
Why?
| | alpha-2-Antiplasmin | 1 | 1987 | 1 | 0.020 |
Why?
| | Fibrinolysin | 1 | 1987 | 1 | 0.020 |
Why?
| | Tyrosine | 1 | 1987 | 2 | 0.020 |
Why?
| | Sulfates | 1 | 1987 | 6 | 0.020 |
Why?
| | Alamethicin | 1 | 2005 | 1 | 0.020 |
Why?
| | Hypolipidemic Agents | 1 | 2005 | 1 | 0.020 |
Why?
| | Uridine Diphosphate Glucuronic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| | Glucuronates | 1 | 2005 | 2 | 0.020 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2005 | 3 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 94 | 0.020 |
Why?
| | Macaca fascicularis | 1 | 1998 | 2 | 0.010 |
Why?
| | Bile | 1 | 1998 | 2 | 0.010 |
Why?
| | Rats, Wistar | 1 | 1998 | 2 | 0.010 |
Why?
| | Blood Proteins | 1 | 1998 | 3 | 0.010 |
Why?
| | Species Specificity | 1 | 1998 | 10 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1998 | 11 | 0.010 |
Why?
| | Erythrocytes | 1 | 1998 | 11 | 0.010 |
Why?
| | Administration, Oral | 1 | 1998 | 58 | 0.010 |
Why?
| | Rats | 1 | 1998 | 106 | 0.010 |
Why?
| | Kidney | 1 | 1998 | 94 | 0.010 |
Why?
| | Mice | 1 | 1998 | 348 | 0.010 |
Why?
| | Cyanogen Bromide | 1 | 1987 | 1 | 0.000 |
Why?
| | Trypsin | 1 | 1987 | 1 | 0.000 |
Why?
| | Hydrolysis | 1 | 1987 | 3 | 0.000 |
Why?
| | Binding Sites | 1 | 1987 | 26 | 0.000 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|